Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway

Molecular Diagnosis and Therapy

Volumn 14, Issue 3, 2010, Pages 155-161

  Wang, Wei Qiang ^a   Zhang, Hao ^a   Wang, Hong Bin ^a   Sun, Yong Gang ^a   Peng, Zhi Hong ^a   Zhou, Gang ^a   Yang, Shi Ming ^a   Wang, Rong Quan ^a   Fang, Dian Chun ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

1 Phosphatidylinositol 3 kinase inhibitors, general; Gastric cancer; Gastric cancer, Proto oncogene protein c akt modulators, general; PI3KAkt pathway; Programmed cell death 4; TNF related apoptosis inducing ligand modulators, general; Tumor necrosis factor related apoptosis induced ligands

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; COMPLEMENTARY DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED CELL DEATH 4 PROTEIN; PROTEIN KINASE B; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION; WESTERN BLOTTING;

EID: 77954106330     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/BF03256368     Document Type: Article

References (49)

1. Yagita H, Takeda K, HayakawaY, et al. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004; 95: 777-783
2. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008; 263: 14-25
3. Ozoren N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003; 13: 135-147
4. Panner A, Parsa AT, Pieper RO. Translational regulation of TRAIL sensitivity. Cell Cycle 2006; 5: 147-150
5. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162
6. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559-563
7. Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 2005; 65: 6034-6041
8. Hilliard A, Hilliard B, Zheng SJ, et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol 2006; 177: 8095-8102
9. Yang HS, Matthews CP, Clair T, et al. Tumorigenesis suppressor Pdcd4 downregulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol 2006; 26: 1297-1306
10. Cmarik JL,Min H, Hegamyer G, et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci U S A 1999; 96: 14037-14042
11. Yang HS, Jansen AP, Nair R, et al. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kappaB or ODC transactivation. Oncogene 2001; 20: 669-676
12. Yang HS, Knies JL, Stark C, et al. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 2003; 22: 3712-3720
13. Goke R, Barth P, Schmidt A, et al. Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1).AmJ Physiol Cell Physiol 2004; 287: C1541-6
14. Gao F, Zhang P, Zhou C, et al. Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma. Oncol Rep 2007; 17: 123-128
15. Zhang H, Ozaki I, Mizuta T, et al. Involvement of programmed cell death 4 in transforming growth factor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene 2006; 25: 6101-6112
16. Chen Y, Knosel T, Kristiansen G, et al. Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol 2003; 200: 640-646
17. Lankat-Buttgereit B, Gregel C, Knolle A, et al. Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II. Mol Cell Endocrinol 2004; 214: 149-153
18. Jin H, Kim TH, Hwang SK, et al. Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol Cancer Ther 2006; 5: 1041-1049
19. Jansen AP, Camalier CE, Stark C, et al. Characterization of programmed cell death 4 inmultiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther 2004; 3: 103-110
20. Chen X, Thakkar H, Tyan F, et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 2001; 20: 6073-6083
21. Thakkar H, Chen X, Tyan F, et al. Pro-survival function of Akt/protein kinase B in prostate cancer cells: relationship with TRAIL resistance. J Biol Chem 2001; 276: 38361-38369
22. Lane D, Robert V, Grondin R, et al. Malignant ascites protect against TRAILinduced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 2007; 121: 1227-1237
23. Bellacosa A, Chan TO, Ahmed NN, et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998; 17: 313-325
24. Chan TO, Rittenhouse SE, Tsichlis PN. AKT/PKB and other D3 phosphoinositide- regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation. Annu Rev Biochem 1999; 68: 965-1014
25. Palamarchuk A, Efanov A, Maximov V, et al. Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res 2005; 65: 11282-11286
26. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003; 4: 257-262
27. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 2001; 98: 10983-10985
28. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002; 14: 381-395
29. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501
30. Yan W, Fu Y, Tian D, et al. PI3 kinase/Akt signaling mediates epithelialmesenchymal transition in hypoxic hepatocellular carcinoma cells. Biochem Biophys Res Commun 2009; 382: 631-636
31. Capodanno A, Camerini A, Orlandini C, et al. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum Pathol 2009; 40: 1408-1417
32. Olson A, Sheth N, Lee JS, et al. RNAi Codex: a portal/database for shorthairpinRNA( shRNA) gene-silencing constructs. Nucleic Acids Res 2006; 34: D153-7
33. Nagane M, Pan G, Weddle JJ, et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 847-853
34. Kim K, Fisher MJ, Xu SQ, et al. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6: 335-346
35. Chinnaiyan AM, Prasad U, Shankar S, et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 2000; 97: 1754-1759
36. Kim K, Takimoto R, Dicker DT, et al. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int J Oncol 2001; 18: 241-247
37. Oki E, Baba H, Tokunaga E, et al. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005; 117: 376-380
38. Kobayashi I, Semba S, Matsuda Y, et al. Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma. Pathobiology 2006; 73: 8-17
39. Lin HL, Yang MH, Wu CW, et al. 2-Methoxyestradiol attenuates phosphatidylinositol 3-kinase/Akt pathway-mediated metastasis of gastric cancer. Int J Cancer 2007; 121: 2547-2555
40. Ang KL, Shi DL, Keong WW, et al. Upregulated Akt signaling adjacent to gastric cancers: implications for screening and chemoprevention. Cancer Lett 2005; 225: 53-59
41. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657
42. Dorrello NV, Peschiaroli A, Guardavaccaro D, et al. S6K1- and betaTRCPmediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006; 314: 467-471
43. Schmid T, Jansen AP, Baker AR, et al. Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. Cancer Res 2008; 68: 1254-1260
44. Ozpolat B, Akar U, Steiner M, et al. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res 2007; 5: 95-108
45. Carayol N, Katsoulidis E, Sassano A, et al. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem 2008; 283: 8601-8610
46. Lankat-Buttgereit B, Muller S, Schmidt H, et al. Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line. Biol Cell 2008; 100: 703-715
47. Woodard J, Sassano A, Hay N, et al. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res 2008; 14: 4640-4649
48. Mudduluru G, Medved F, Grobholz R, et al. Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer 2007; 110: 1697-1707
49. Li D, Qu X, Hou K, et al. PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs 2009; 20: 59-64